Antonella Matti

Prof. Antonella Matti

IRCCS Sacro Cuore Don Calabria Hospital, Verona
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2018 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
GLGiacomo Maria Lima
Giacomo Maria Lima
AMAntonella Matti
Antonella Matti
GVGiulio Vara
Giulio Vara
GDGiulia Dondi
Giulia Dondi
NNNicoletta Naselli
Nicoletta Naselli
Stefano FantiStefano Fanti
Stefano Fanti
To investigate the prognostic value of posttreatment 18F-FDG PET/CT in patients with locally advanced cervical cancer (LACC) treated with concomitant chemoradiation therapy (CCRT). The secondary aim was to assess the possible role of intensity-based and volume-based PET parameters including SUVmax, SUVmean, MTV and TLG, and clinical parameters including age, pathology, FIGO stage and nodal involvement as factors predicting response to treatment.

1 May 2019 in Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
AMAntonella Matti
Antonella Matti
GLGiacomo Maria Lima
Giacomo Maria Lima
CPCinzia Pettinato
Cinzia Pettinato
FPFrancesca Pietrobon
Francesca Pietrobon
FMFelice Martinelli
Felice Martinelli
Stefano FantiStefano Fanti
Stefano Fanti

15 November 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LBLuca Bertamini
Luca Bertamini
JNJacopo Nanni
Jacopo Nanni
GMGiovanni Marconi
Giovanni Marconi
MAMariachiara Abbenante
Mariachiara Abbenante
VRValentina Robustelli
Valentina Robustelli
CPCristina Papayannidis
Cristina Papayannidis
Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose mechanism of action relies on the killing of CD22 positive leukemic cells, through the delivery, after cell binding, of a molecule of calicheamicin. We report two cases of CD22 positive relapsed EM-ALL treated with IO, obtained as compassionate use. Case 1, a 66 years old woman, affected by Philadelphia (Ph) negative B-ALL, relapsed with extramedullary involvement after 6 standard chemotherapy courses, who reached a complete metabolic response with IO treatment. Case 2, a 67 years old man with Ph positive B-ALL, initially treated with ponatinib, a third generation tyrosine-kinase inhibitor (TKI), obtaining a prolonged deep molecular remission. Nevertheless, for skin relapse during TKI treatment, the patient received local radiotherapy and, shortly after, standard chemotherapy, as multiple abdominal sites of relapse were detected too, with no response. The patient then received IO, obtained as compassionate use, with a good metabolic response. These two cases suggest a possible key role of IO in the setting of advanced CD22 positive ALL, and underline its potential activity also in patients with EM involvement, relapsed after or refractory to conventional chemotherapy. Despite the well known hepatotoxic effect of the compound (Sinusoid Occlusive Syndrome), neither of them had such adverse event, moreover the second patient safely underwent allogeneic bone marrow transplantation.

23 January 2018 in Future Oncology
Verified
Journal Article
Closed access
LZLucia Zanoni
Lucia Zanoni
IBIrene Bossert
Irene Bossert
AMAntonella Matti
Antonella Matti
RSRiccardo Schiavina
Riccardo Schiavina
CPCristian Pultrone
Cristian Pultrone
CNCristina Nanni
Cristina Nanni
A significant number of patients radically treated for prostate cancer (PCa) will develop prostate-specific antigen recurrence (27–53%). Localizing the anatomical site of relapse is critical, in order to achieve the optimal treatment management. To date the diagnostic accuracy of standard imaging is low. Several desirable features have been identified for the amino-acid-based PET agent, fluciclovine (18F) including: long 18F half-life which allows more practical use in centers without a cyclotron onsite; acting as a substrate for amino acid transporters upregulated in PCa or associated with malignant phenotype; lacking of incorporation into protein; and limited urinary excretion. Fluciclovine (18F) is currently approved both in USA and Europe with specific indication in adult men with suspected recurrent PCa based on elevated prostate-specific antigen following prior treatment. Lay summary Fluciclovine (18F) is a novel radiotracer for PET imaging, initially developed for neuro-oncology, then tested in a variety of tumors characterized by an increased need of amino acid uptake. Results in prostate cancer were promising. It is currently approved both in USA and Europe with specific indication in adult men with suspected recurrent prostate cancer based on elevated prostate-specific antigen, following prior treatment.

29 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LZLucia Zanoni
Lucia Zanoni
RMRiccardo Mei
Riccardo Mei
LBLorenzo Bianchi
Lorenzo Bianchi
FGFrancesca Giunchi
Francesca Giunchi
LMLorenzo Maltoni
Lorenzo Maltoni
Stefano FantiStefano Fanti
Stefano Fanti
The primary aim of the study was to evaluate the role of [18F]Fluciclovine PET/CT in the characterization of intra-prostatic lesions in high-risk primary PCa patients eligible for radical prostatectomy, in comparison with conventional [11C]Choline PET/CT and validated by prostatectomy pathologic examination. Secondary aims were to determine the performance of PET semi-quantitative parameters (SUVmax; target-to-background ratios [TBRs], using abdominal aorta, bone marrow and liver as backgrounds) for malignant lesion detection (and best cut-off values) and to search predictive factors of malignancy. A six sextants prostate template was created and used by PET readers and pathologists for data comparison and validation. PET visual and semi-quantitative analyses were performed: for instance, patient-based, blinded to histopathology; subsequently lesion-based, un-blinded, according to the pathology reference template. Among 19 patients included (mean age 63 years, 89% high and 11% very-high-risk, mean PSA 9.15 ng/mL), 45 malignant and 31 benign lesions were found and 19 healthy areas were selected (n = 95). For both tracers, the location of the “blinded” prostate SUVmax matched with the lobe of the lesion with the highest pGS in 17/19 cases (89%). There was direct correlation between [18F]Fluciclovine uptake values and pISUP. Overall, lesion-based (n = 95), the performance of PET semiquantitative parameters, with either [18F]Fluciclovine or [11C]Choline, in detecting either malignant/ISUP2-5/ISUP4-5 PCa lesions, was moderate and similar (AUCs ≥ 0.70) but still inadequate (AUCs ≤ 0.81) as a standalone staging procedure. A [18F]Fluciclovine TBR-L3 ≥ 1.5 would depict a clinical significant lesion with a sensitivity and specificity of 85% and 68% respectively; whereas a SUVmax cut-off value of 4 would be able to identify a ISUP 4-5 lesion in all cases (sensitivity 100%), although with low specificity (52%). TBRs (especially with threshold significantly higher than aorta and slightly higher than bone marrow), may be complementary to implement malignancy targeting.

15 November 2017 in European Journal of Hybrid Imaging
Verified
Journal Article
Open access
PDF file
GLG. M. Lima
G. M. Lima
AMAntonella Matti
Antonella Matti
LBL. Burgio
L. Burgio
CNC. Nanni
C. Nanni
PCP. Castellucci
P. Castellucci
SFS. Fanti
S. Fanti
Only about 1% of all head and neck lateral or paramedian cancers described in the scientific literature shows, in staging, contralateral cervical adenopathy without ipsilateral pathological involvement of lymph nodes. This case is one of them, in which 18F–FDG PET/CT scan is confirmed by pathology findings, and has correctly identified all metastatic disease foci. To date, PET/CT is not recommended in head and neck cancer staging. However, the use of PET/CT in head and neck cancer staging can define possible metastatic disease foci, clarify c.e. CT suspicious findings and, in some cases, change the TNM stage, with a strong prognostic and therapeutic impact.